Thursday, February 09, 2017 12:59:41 PM
a post six months ago: senrex, Bavi as a "dud" is not a realistic description of it in light of current knowledge about it and about the now-burgeoning field of aminopholipid biochemistry. The "dud" part of Bavi, if there is one, is in current and past choices of clinical application. However, I cannot imagine for a moment that those scientists involved in this aminopholipid sector are going to come up empty-handed, and PPHM has an enormous lead in the sector. One problem is that the salutary and relatively side-effect free anti-inflammatory and anti-tumor effects observed ad nauseam (and financed by us stockholders) in pre-clinical testing must be investigated in humans in relatively short time-frames driven mostly by economic considerations rather than realistic therapeutic treatment durations. Simply-put, I would be willing to bet even more investment dollars that Bavi, or similar, will be a life-extender to almost all biological forms subject to inflammation and tumor formation if taken(for instance) as a daily nasal spray (since it has been established to easily enter the bloodstream after passing through the nasal mucosa). How do we measure life extension and generalized improvement in "well-being" in a reasonable period of time? Killing advanced lung cancers, as we have seen in multiple I-O failures lately, is not a reasonable expectation. As mentioned several times here, the "spin-offs" from trials of one purpose are often more valuable than the stated goal and end-point of the trial, so those of us here involved the clinical arena are keeping our fingers crossed that the post-hoc findings of the Bavi PIII trial (autopsy review of various organs systems and Bavi-specific staining of accumulation in various organs, infection sites AND tumor) will be productive. We are fortunate, as a small biotech, to have in our grasp such a wealth of human material to study after treatment with one of our lead products. We are also obligated to all patients and stockholders to make the most of this opportunity. The biggest hurdle has been overcome, presumably, and that is SAFETY. Pharma is full of agents that kill tumors, but kill patients too. Now the search is on for the correct application of potentially a myriad antiphospholipid MABs. Let's give some credit where it is due.
Recent CDMO News
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM